Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 17, 1997

View Archived Issues

Inhale Therapeutic Systems: Q3 1997 highlights

Chiroscience: HY 1997 highlights

Yamanouchi: Annual Report 1997

Sequence of S. epidermidis revealed

Abbott and Biorex to collaborate on bimoclomol development

Therapeutic Antibodies and Altana enter alliance for emergency medicine products

Fujisawa launches new OTC product

COX-2 inhibitors from Chugai

Antiinfective and immunomodulatory micacocidin derivatives from Shionogi

Alpha1-antichymotrypsin analogues described in patent literature

Health Research claims peptide inhibitor of growth factors

Peptide drugs for treating leishmaniasis

BIRR-4: a new cold remedy on the horizon?

SKB claims 5-HT7 receptor antagonists

New dopamine beta-hydroxylase inhibitors derived from lettuce

AMPA receptor antagonists prepared at Schering AG

Byk Gulden describes new agents for asthma

P&G develops dihydrobenzofuran compounds for inflammation

VZV vaccines using gene product expressed during latency

Toxicity studies reported for new expectorant from SS Pharm.

Draflazine: a potential cardioprotectant with a novel mechanism of action

CS-834: a new oral carbapenem in active development at Sankyo

U-101033E vs. U-74389G in rat model of focal cerebral ischemia

Agouron to collaborate with U.K. organizations in search for anticancer drugs

Diagnon receives NCI grant for H. pylori research

New GVAX cancer vaccine begins human testing

Switch OTCs for allergies to be introduced by Fujisawa

FDA approves Follistim for IVF and ovulation induction

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...